Athos Capital’s Aspire Biopharma Warrant ASBPW Stock Holding History

Athos Capital’s Portfolio ASBPW Stock Details ASBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,383	Closed	-$1K	–	52
2026 Q1	$1K	Hold	21,383	–	–	﹤0.01%	44
2025 Q4	$3K	Buy	+21,383	New	+$659	﹤0.01%	37
2025 Q3	–	Sell	-21,383	Closed	-$6K	–	48
2025 Q2	$6K	Hold	21,383	–	–	0.01%	35
2025 Q1	$12K	Hold	21,383	–	–	0.01%	41
2024 Q4	$246K	Hold	21,383	–	–	0.11%	29
2024 Q3	$261K	Hold	21,383	–	–	0.08%	25
2024 Q2	$241K	Hold	21,383	–	–	0.13%	31
2024 Q1	$236K	Hold	21,383	–	–	0.25%	31
2023 Q4	$233K	Hold	21,383	–	–	0.26%	29
2023 Q3	$232K	Sell	21,383 -3,616	-14%	-$292	0.12%	45
2023 Q2	$264K	Hold	24,999	–	–	0.21%	58
2023 Q1	$262K	Hold	24,999	–	–	0.18%	72
2022 Q4	$257K	Buy	+24,999	New	+$1.68K	0.15%	90

Other funds holding ASBPW

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Athos Capital's ASBPW Position: Q2 2026 in Review

Athos Capital sold out of Aspire Biopharma Warrant (ASBPW) in Q2 2026, closing a stake of 21,383 shares — an estimated $1K sold.

Athos Capital first reported a position in ASBPW in Q4 2022 and held it in 13 quarters. The position peaked at $264K in Q2 2023. 27 funds tracked by Wall St. Rank hold ASBPW as of Q2 2026.

Athos Capital reported no remaining Aspire Biopharma Warrant position as of Q2 2026 after selling out during the quarter.
Athos Capital sold 21,383 Aspire Biopharma Warrant shares in Q2 2026, an estimated $1K.
Athos Capital first reported a position in Aspire Biopharma Warrant in Q4 2022 and held it in 13 quarters.
Athos Capital's Aspire Biopharma Warrant position peaked at $264K in Q2 2023.
27 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2026.

Based on Athos Capital's 13F filing for Q2 2026, filed 13 Aug 2026.